GLOBAL INVESTIGATION — A newly published, peer-reviewed study in the EXCLI Journal has reignited intense debate surrounding the safety transparency of mRNA COVID-19 vaccines. The research, which analyzed hundreds of Israeli Ministry of Health (MOH) hospitalization records and mortality data spanning from March 2021 to May 2022, alleges that both pharmaceutical giant Pfizer and Israeli health authorities were aware of emerging cardiac safety signals months before any public warnings were issued to physicians or the general population.
The findings center on a critical window in early 2021, when Israel rolled out one of the world’s most aggressive and rapid inoculation campaigns using the Pfizer-BioNTech Wuhan coronavirus (COVID-19) vaccine. According to the study and supporting investigative reports, early warnings regarding heart inflammation—specifically myocarditis and pericarditis, predominantly affecting young males—were circulating among high-level health officials while public messaging continued to characterize the injections as uniformly "safe and effective."
The implications of the paper stretch far beyond Israel’s borders, drawing renewed scrutiny toward global public health agencies, including the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), regarding how potential adverse events were monitored, interpreted, and communicated during the height of the pandemic.
Main Facts and Core Findings
The EXCLI Journal study provides a granular breakdown of 531 Israeli Ministry of Health hospitalization records and 67 deaths collected between March 2021 and May 2022. The core data reveals a disproportionate concentration of heart-related inflammatory conditions among younger demographics shortly after vaccination.
Key data points highlighted in the study include:
- High Prevalence of Heart Inflammation: Myocarditis or pericarditis was documented in 250 out of the 531 total hospitalization records, accounting for 47.1% of the dataset.
- Severe Impact on Young Adults: Among 211 patients under the age of 30, heart inflammation appeared in 151 records, representing 71.6% of that cohort. Of these younger patients, 134 had no prior meaningful medical history, and 99 were officially diagnosed with myocarditis or pericarditis, with young males making up the vast majority of cases.
- Pediatric and Young Adult Fatalities: The study flagged myocarditis-related deaths in individuals under 50 years old, explicitly noting a 22-year-old woman and a 47-year-old man. Furthermore, 48 patients under the age of 18 were recorded as having developed myocarditis or pericarditis.
- Rapid Onset: Symptom onset for these cardiac events consistently occurred within days to a few weeks following the administration of the vaccine doses.
The publication of these figures adds to a growing body of independent medical literature examining post-vaccination cardiac events. For instance, earlier studies published in JAMA Cardiology and Pediatrics similarly documented clusters of acute myocarditis in otherwise healthy military service members and adolescent boys shortly following their second doses of Pfizer or Moderna mRNA vaccines.
Chronology of Awareness and Delayed Disclosures
The timeline constructed by the EXCLI Journal study and complementary Freedom of Information Act (FOIA) disclosures outlines a significant delay between internal government realizations and public transparency.
- Late February 2021: Just over two months after Israel launched its mass vaccination drive, the Israeli Ministry of Health identified an emerging cardiac safety signal. On February 28, 2021, Israeli health authorities reportedly alerted health counterparts in the United States, including the CDC, regarding approximately 40 localized cases of myocarditis.
- March to May 2021: Internal records show Pfizer was actively receiving reports of deaths and hospitalizations. A notable Pfizer report dated March 25, 2021, contained information on 157 hospitalizations and 46 deaths. Despite this data flow, public warnings were not issued. Information regarding the Israeli Ministry ofhind-the-scenes alerts did not become public until February 23, 2023, following a FOIA request filed by Children’s Health Defense (CHD).
- April and May 2021 Public Denials: As internal communications flagged safety signals, public-facing institutions pushed back. On April 26, 2021, the CDC and FDA publicly denied the existence of a safety signal connecting the mRNA vaccines to myocarditis. It was not until late May 2021 that the CDC formally recommended that clinicians report all cases of post-vaccination heart inflammation.
- June 2022 Leaks and Subsequent Reports: Leaked video recordings from June 2022 revealed that independent researchers presented data to the Israeli Ministry of Health highlighting serious, long-term side effects tied to the Pfizer shot. Yet, in an August 2022 public report, Israeli health officials maintained that serious side effects were exceptionally "rare" and short-lived.
Critics argue this timeline demonstrates a systemic failure in the precautionary principle, leaving millions of individuals unaware of emerging risks while making decisions about subsequent doses.
Supporting Data and Dataset Irregularities
Beyond the clinical outcomes, the EXCLI Journal study raises profound questions regarding the integrity and handling of government health datasets during the pandemic. The study authors noted that the Israeli Ministry of Health’s internal database underwent multiple undocumented revisions.
According to the research:
- Clinical information, dates, and formal diagnoses were frequently altered or omitted across successive versions of the dataset.
- Specific mortality records present in the October 2021 dataset mysteriously vanished from the December 2021 and later iterations.
- The dataset lacked standard methodological documentation or a formal audit trail, complicating independent scientific verification.
These data management practices have drawn sharp criticism from data scientists and epidemiologists who argue that transparency is vital for public trust and accurate post-market safety surveillance. The absence of a clear audit trail, critics note, makes it difficult to ascertain the exact volume of adverse events experienced during the peak rollout phases.
Official Responses and Expert Reactions
The release of the study has provoked strong reactions from medical professionals, independent researchers, and advocacy groups worldwide, highlighting a deep fracture between institutional public health bodies and independent watchdogs.
Karl Jablonowski, Ph.D., a senior research scientist for Children’s Health Defense, pointed out a glaring discrepancy between institutional safety claims and reality. Jablonowski noted that none of the severe myocarditis-related deaths analyzed in the study appeared to be successfully captured within the U.S. Vaccine Adverse Event Reporting System (VAERS), despite pharmaceutical obligations to log such events. "The bereaved and the injured are owed an answer," Jablonowski stated.
Steve Kirsch, founder of the Vaccine Safety Research Foundation, asserted that the study carries immense weight because it relies directly on internal government data. Kirsch contended that the findings indicate the Israeli Ministry of Health "was clearly more interested in protecting the manufacturers than the public."
Echoing these concerns, Dr. Jane Orient, executive director of the Association of American Physicians and Surgeons, argued that the situation in Israel is reflective of a global systemic breakdown. "I don’t think Israel is an outlier," Dr. Orient remarked. "Pharmaceutical companies, public health authorities, organized medicine, and academics worldwide have performed shamefully and betrayed our trust."
Meanwhile, official public health bodies have historically maintained that the benefits of mRNA vaccination heavily outweigh the known risks, categorizing post-vaccination myocarditis as a rare and typically mild condition that resolves quickly with standard medical care. However, agencies have progressively updated their warning labels and guidance to acknowledge the association, particularly among young adolescent and adult males following the second dose.
Implications for Informed Consent and Public Policy
The core thesis of the EXCLI Journal paper—that critical safety data was withheld from the public for months—strikes directly at the heart of medical ethics and the principle of informed consent.
Epidemiologist M. Nathaniel Mead, Ph.D., emphasized that genuine informed consent requires transparent, granular, and timely communication of risks. According to Mead, patients—particularly young males who face the highest relative risk of vaccine-induced cardiac events—should have been provided age- and sex-specific risk disclosures. Such information would have empowered individuals to make individualized medical choices, such as delaying a second dose or opting for alternative vaccination strategies.
The findings also cast a long shadow over regulatory oversight. Internal Pfizer documents evaluated by the independent investigative group DailyClout indicated that the pharmaceutical company was actively studying myocarditis in children as young as five a month before the FDA authorized the shots for that specific pediatric age group. Concurrently, the CDC continued to aggressively promote the injections as universally "safe and effective" for children.
Legal and medical analysts suggest that these revelations may fuel ongoing legal challenges regarding vaccine mandates, liability protections for pharmaceutical manufacturers, and the adequacy of adverse event monitoring systems globally. Critics argue that the established pattern—whereby health authorities repeatedly categorized post-vaccination deaths and severe injuries as coincidental rather than causal—has inflicted lasting damage on public confidence in institutional medicine.
As researchers continue to parse through leaked documents, FOIA releases, and retrospective health data, the demand for independent, transparent, and unaccountable public health inquiries grows louder. Whether the medical establishment will formally reevaluate its approach to post-market surveillance and risk communication in light of these findings remains one of the most contentious issues in modern public health policy.
